30 day Reponse

Attachment_C_Comments_and_Response_to_Federal_Register_Notice_2020_30 da.._ (005).docx

Medicare Advantage and Prescription Drug Program: Final Marketing Provisions CFR 422.111(a)(3) and 423.128(a)(3) (CMS-10260)

30 day Reponse

OMB: 0938-1051